陈晓光，1958年生，籍贯辽宁省锦西，肿瘤药理学家，药物研究所研究员，博士生导师。1978年04月考入佳木斯医学院医疗系医学专业，1982年获得学士学位。1985年08月在黑龙江中医学院基础药理学专业攻读硕士学位，从事心血管药理学研究。1992年08月在北京协和医学院药理学专业攻读博士学位，从事肿瘤分子药理学研究。1995年升为助理研究员。1996年为副研究员，1999年为研究员。

主要从事抗肿瘤药物的分子药理学研究及新药创制与开发，免疫调节剂的研究与开发，主要研究领域为抗肿瘤药物研究新靶点- MEKK1、PARP1/2、PIN1、HIF-1、HSP90、IDO1/TDO、PD1/PD-L1、LAG3、NOD1/NOD2等抑制剂，PI3K、STAT3、Hedgehog等信号通路抑制剂以及与免疫调节密切相关的S1P1受体激动剂和TGF-b抑制剂等方面的研究。

天美麻花星空视频

1. Ming Ji^#, Dongjie Wang^#, Songwen Lin, Chunyang Wang, Ling Li, Zhihui Zhang, Jing Jin, Deyu Wu, Yi Dong, Heng Xu*, Duo Lu *, Xiaoguang Chen*. A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models. Acta Pharmaceutica Sinica B, 2022 February;12（2）：774-786 (IF=14.911)

2. Kehui Zhang^#, Ming Ji^#, Songwen Lin, Shouguo Peng, Zhihui Zhang, Mingyi Zhang, Jingbo Zhang, Yan Zhang, Deyu Wu, Hua Tian, Xiaoguang Chen*, and Heng Xu*. Design, Synthesis, and Biological Evaluation of a Novel Photocaged PI3K Inhibitor toward Precise Cancer Treatment. Journal of Medicinal Chemistry. 2021 64 (11), 7331-7340 (IF=8.039)

3. Jie Zhou^#, Ming Ji^#, Xiaoyu Wang, Hailong Zhao, Ran Cao, Jing ，Jin, Yan Li, Xianhong Chen, Li Sheng*, Xiaoguang Chen*, and Bailing Xu*. Discovery of Quinazoline-2,4(1H,3H)-dione Derivatives Containing 3-Substituted Piperizines as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis. Journal of Medicinal Chemistry, 2021, 64 (22), 16711-16730 (IF=8.039)

4. Yi Dong^#, Rong Fu^#, Jiajing Chen, Kehui Zhang, Ming Ji, Mingjin Wang, Huimin Jiang, Wei Ye, Jinping Hu, Yan Li, Jing Jin, Xiaoguang Chen*, Heng Xu*. Discovery of Benzocyclic Sulfone Derivatives as Potent CXCR2 Antagonists for Cancer Immunotherapy Journal of Medicinal Chemistry. 2021 Nov 25:64(22):16626-16640. (IF=7.446)

5. Zhao Z^#, Wang X, Qu J, Zuo W, Tang Y*, Zhu H,* Chen X*. Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 15;11:708195. (IF=6.244)

6. Jing Jin^#, Nina Xue^#, Yuan Liu, Rong Fu, Mingjin Wang, Ming Ji, Fangfang Lai, Jinping Hu, Xiaojian Wang, Qiong Xiao, Xiaoying Zhang, Dali Yin,Liping Bai, Xiaoguang Chen^*, Shuan Rao^*. A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models. Acta Pharmaceutica Sinica B. 2020 Feb;10(2):276-288. (IF=11.614)

7. Songwen Lin^#, Jing Jin^#, Ying Liu^#, Hua Tian, Yan Zhang, Rong Fu, Jingbo Zhang, Mingjin Wang, Tingting Du, Ming Ji, Deyu Wu, Kehui Zhang, Li Sheng, Yan Li, Xiaoguang Chen^*, Heng Xu^*. Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis. J Med Chem. 2019 Oct 10;62(19):8873-8879. (IF=6.205)

8. Nina Xue^#, Fangfang Lai^#, Tingting Du, Ming Ji, Di Liu, Chunhong Yan, Sen Zhang, Xiaoming Yu, Jing Jin^*, Xiaoguang Chen^*. Chaperone-mediated autophagy degradation of IGF-1Rβ induced by NVP-AUY922 in pancreatic cancer. Cell Mol Life Sci. 2019 Sep;76(17):3433-3447. (IF=6.496)

9. Zhang Kehui^#, Lai Fangfang^#, Lin Songwen, Ji Ming, Zhang Jingbo, Zhang Yan, Jin Jing, Fu Rong, Wu Deyu, Tian Hua, Xue Nina, Sheng Li, Zou Xiaowen, Li Yan, Chen Xiaoguang^*, Xu Heng^*. Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. J Med Chem. 2019 Aug 8;62(15):6992-7014. (IF=6.205)

10.Songwen Lin^#, Chunyang Wang^#, Ming Ji, Deyu Wu, Yuanhao Lv, Kehui Zhang, Yi Dong, Jing Jin, Jiajing Chen, Jingbo Zhang, Li Sheng, Yan Li, Xiaoguang Chen^*, Heng Xu^*. Discovery and Optimization of 2 Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3 Kinase Inhibitors for Cancer Treatment. J Med Chem. 2018 Jul 26;61(14):6087-6109. (IF=6.054)